BioCentury | Nov 3, 2020

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

JW makes public debut on Hong Kong exchangeIn its first day of trading Tuesday, JW Therapeutics Co. Ltd. (HKEX:2126) fell HK$1.80 to HK$22 after raising HK$2.3 billion ($300 million) in an IPO. Bristol Myers Squibb...
BioCentury | Jul 10, 2020
Product Development

IQVia’s Dreyer on how real-world data are poised to break new ground

Real-world data isn’t just about post-market analysis of new drugs and vaccines. With the pandemic putting the benefits on display, epidemiologists are finding new ways to use the data, and new data sources, to support...
BioCentury | Jul 10, 2020
Tools & Techniques

Precise base editing of mitochondrial DNA

David Liu and colleagues at the Broad Institute and University of Washington have achieved single-base editing of mitochondrial DNA for the first time, overcoming a limitation of CRISPR-based technologies and opening up new avenues for...
BioCentury | Jun 17, 2020
Emerging Company Profile

Lightspeed, Klausner back Stanford cell therapy spinout Orca in new $192M round

With the completion of a new $192 million series D round, Stanford spinout Orca Bio has now raised nearly $300 million to develop and manufacture allogeneic cell therapies that use controlled formulations designed to reduce...
BioCentury | Apr 9, 2020

Wuhan gene therapy play Neurophth raises $18M series A

Neurophth has raised RMB130 million ($18.4 million) in a series A round with plans to bring an ophthalmology gene therapy to market in three to five years. Sequoia Capital China and Fosun’s InnoStar Venture led...
BioCentury | Mar 28, 2020
Product Development

COVID-19 diagnostic tech tableau

In the ramp-up of testing for COVID-19, two well-established technologies have divided the forefront: RT-PCR and immunoassays. The former tests for active infection by detecting viral RNA, while the latter can be used to detect...
BioCentury | Mar 9, 2020

With $22M B round, Numab to build out multispecific mAb pipeline

Following a run of partnerships with Asian companies, Numab has closed a series B round to enable the Swiss biotech to focus on expanding its pipeline of multispecific mAbs. Numab Therapeutics AG announced Monday that...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

...move into the clinic within a year. It also has preclinical assets targeting TRMP7 and Src-ND2...
...“I hope our success will spur others to try to develop neuroprotectants.” Targets ND2 - NADH dehydrogenase subunit 2...
BioCentury | Oct 8, 2019
Company News

After remedies to NDA, Intarcia’s diabetes implant under FDA review again

More than two years after well-funded Intarcia received a complete response letter from FDA, an NDA for the company’s implantable pump to treat Type II diabetes is back under the agency’s review. The new PDUFA...
BioCentury | Aug 31, 2019
Product Development

Digital dollars: financing for digital health

The heyday of digital health may not yet even be on the horizon, but investments in the field are certainly starting to hit the radar in the areas most likely to impact patients first --...
Items per page:
1 - 10 of 445